Embecta agreed to acquire Owen Mumford Holdings Limited for up to $200 million (150 million pounds), including a $134 million upfront payment and up to $67 million in performance-based payments. The acquisition aims to enhance Embecta's drug-delivery capabilities and expand into chronic care markets. The deal is expected to close in Q3 fiscal 2026 and contribute to revenue growth from fiscal 2027 onward, though it will be dilutive to adjusted net income in 2027. Embecta shares rose 4.63% to $8.98 on the announcement.

Embecta Corp has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technology company, for up to £150 million (£100 million upfront plus up to £50 million in performance-based payments). The acquisition is expected to expand embecta's product portfolio, accelerate growth in chronic care markets, and leverage complementary manufacturing capabilities and global commercial infrastructure.

The article examines three high-yielding healthcare stocks: Perrigo (8.2% yield) is cautioned as a potential value trap despite strong dividend history; Pfizer (6.7% yield) is viewed more favorably with post-COVID catalysts and GLP-1 product launches; Embecta (5.5% yield) shows turnaround potential as it pivots toward the GLP-1 pen needle business.

Embecta Corp. (Nasdaq: EMBC) announced a quarterly cash dividend of $0.15 per share, payable on March 17, 2026 to shareholders of record as of February 27, 2026. The company continues its operations as a global medical supplies provider focused on insulin delivery solutions.

Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced it will host a conference call on February 5, 2026, at 8:00 a.m. ET to discuss its fiscal first quarter 2026 financial results and provide an operational update. The live webcast will be accessible via the company's investor relations website.

Embecta Corp. declared a quarterly cash dividend of $0.15 per share, payable on December 18, 2025. The company also announced board changes, with David J. Albritton resigning and David F. Melcher planning to retire.

Embecta Corp. announced two board member departures: David J. Albritton resigning immediately and LTG David F. Melcher retiring at the 2026 annual stockholder meeting. The company plans to appoint Dev Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director.

Embecta Corp. will host a conference call on November 25, 2025, at 8:00 a.m. ET to discuss its fiscal fourth quarter and full year 2025 financial results and provide preliminary fiscal year 2026 financial guidance.

Embecta Corp. announced participation in two upcoming investor conferences in September 2025, including a fireside session at the Wells Fargo Healthcare Conference and one-on-one investor meetings at the Morgan Stanley Global Healthcare Conference.

Embecta Corp. announced a quarterly cash dividend of $0.15 per share, payable on September 15, 2025, to stockholders of record as of August 29, 2025.

Embecta Corp. will host a conference call on August 8, 2025, at 8:00 a.m. ET to discuss its fiscal third quarter 2025 financial results and provide an operational update.

Embecta Corp., a global diabetes care company, reported its financial results for the second quarter of fiscal 2025. The company also announced its participation in various investor events.